We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Drug Resistance Testing Is Essential for TB Prognosis

By LabMedica International staff writers
Posted on 08 Sep 2010
Tuberculosis is diagnosed in the laboratory by staining sputum smears with the Ziehl-Neelsen acid-fast stain.

However, multi-drug-resistant tubercle bacilli (MDR-TB) cannot be identified by this method. More...
The standard way to test for drug susceptibility is by culturing the bacteria Mycobacterium tuberculosis on Löwenstein-Jensen (LJ) or by the microscopic observation drug susceptibility (MODS) assay.

A study on MDR-TB with 93 participants in a larger study of directly observed therapy was conducted at the Imperial College London (London, UK). The median time for smears and cultures to turn negative was 17.5 days and 38.5 days, respectively. Most patients (90%) were smear-negative by 47.5 days and culture-negative by 93 days. In Peru, for example, the authors found that only 25% of patients with culture-positive MDR-TB were sputum smear-positive after two months of anti-tuberculosis treatment.

The authors point out that when treatment began, 66.7% of patients with culture-positive MDR-TB had positive sputum smears. After two months of treatment, only 25% had positive smears, and after four months, only 20% were smear-positive.

However, more than half of MDR patients remained culture positive even after six months of treatment. Overall, among patients who remained culture positive after two months of directly observed treatment, only 18.8% were sputum smear positive. Persistent smear positivity at day 60 is a poor predictor of MDR and thus not a good surrogate for drug susceptibility testing.

David A. Moore, M.D., the senior author of the study, said, "The industrialized-world convention of universal baseline drug sensitivity testing for tuberculosis patients should become the standard of care in multidrug resistance-affected resource-limited settings. Patients are more infectious on treatment than we previously believed, even when they are on the right treatment." This is important in developing countries where diagnosis of drug resistance is delayed due to lack of drug sensitivity testing and patients remain infectious for longer periods.

The study, published in August 2010 in Clinical Infectious Diseases demonstrates that patients with TB who have fully susceptible disease remain sputum culture positive for much longer than is conventionally believed, regardless of baseline smear status. The influence of baseline sputum bacillary load on smear and culture conversion is relatively minor except at very high smear positivity. Conversion from smear or culture positivity to negativity is significantly delayed by both MDR and resistance that is not MDR, but the relative importance varies, depending on the drug susceptibility test method used to define resistance.

Related Links:
Imperial College London


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Sample Transportation System
Tempus1800 Necto
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The VeraBIND Tau assay is a novel blood test that identifies the presence of active tau pathology (Photo courtesy of 123RF)

First Blood-Based Test Measures Key Alzheimer's Biomarker in Asymptomatic and Symptomatic Individuals

Alzheimer’s disease (AD), the sixth leading cause of death in the United States, affects an estimated 7.2 million Americans aged 65 or older. Current diagnostic methods for AD are often invasive, expensive,... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.